Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:33 PM
Ignite Modification Date:
2025-12-24 @ 2:33 PM
NCT ID:
NCT00980759
Eligibility Criteria:
Inclusion Criteria:
1. Patients (who have been adequately clinically staged) with primary, untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, FIGO stage IB1 with pelvic lymph node metastasis, IB2, IIA(≥4cm in tumor size, or pelvic LN metastasis), IIB, IIIA, IIIB with only unilateral pelvic wall extension, and IVA
2. Patients with negative, para-aortic lymphadenopathy determined by pelvic MRI and/or PET/CT scan.
3. Patients with adequate bone marrow function: ANC greater than or equal to 1,500/ul, platelets greater than or equal to 100,000/ul at the beginning.
4. Patients with adequate renal function: creatinine equal to or less than 2.0 mg/dL.
5. Patients who have signed an approved informed consent and authorization
6. Patients who have met the pre-entry requirements specified in section 6.0.
7. Patients with ECOG Performance Status of 0, 1, 2 and Karnofsky Performance Scale of 100, 90, 80, 70, 60, 50
8. Age: 18≤age≤80
Exclusion Criteria:
1. Stage IIIb with bilateral pelvic wall extension and stage IVB lesions are not eligible.
2. Patients with histology other than squamous, adeno, adenosquamous cell carcinoma
3. Patients who have received prior radiotherapy of pelvis or total hysterectomy Patients who have diagnosis of other malignant tumors other than non- malignant melanoma skin cancer or stage I. II papillary, follicular thyroid cancer.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT00980759
Study Brief:
Protocol Section:
NCT00980759